Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

K. Y. Thong¹ , R. E. J. Ryder¹ , M. L. Cull¹ and C. Walton² on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, City Hospital, Birmingham, UK

²Diabetes, Hull Royal Infirmary, Hull, UK

Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

K.Y. Thong ^a,1, B. Jose ^a,1, A.D. Blann ^a,1, M.L. Cull ^a,1, A.P. Mills^a,1 , T. Sathyapalan^b,1 , C. Walton^b,1 , R.E.J. Ryder^a,1 On behalf of the ABCD nationwide exenatide contributors^†

^aCity Hospital, Birmingham, United Kingdom

^bHull Royal Infirmary, Hull, United Kingdom

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

K. Y. Thong¹, B. Jose¹, N. Sukumar¹, M. L. Cull¹, A. P. Mills¹, T. Sathyapalan², W. Shafiq², A. S. Rigby², C. Walton² & R. E. J. Ryder¹ on behalf of the ABCD nationwide exenatide audit contributors^†

¹Department of Diabetes, City Hospital, Birmingham, UK

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

REJ Ryder¹, KY Thong¹, ML Cull¹, AP Mills¹, C Walton², PH Winocour³ on behalf of the ABCD nationwide exenatide audit contributors^†

¹City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull, UK

³Queen Elizabeth II Hospital, Welwyn Garden City, UK

^†Appendix 1, List of Contributors in the ABCD Nationwide Exenatide Audit

ABCD nationwide audits of new diabetes therapies

Dr Bob Ryder¹

¹City Hospital, Birmingham, UK

“The NHS is open” - Diabetes UK urges parents to be

4Ts aware during lockdown

The guidance in this document is based on experience from UK centres with the greatest experience of looking after patients with COVID-19 disease and will be updated as more evidence becomes available.  The document provides helpful algorithms for management and treatment.

Caution - COVID-19 infection in people with or without previously recognised diabetes increases the risk of the EMERGENCY states of hyperglycaemia with ketones, Diabetic KetoAcidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS)

Combined liraglutide-insulin therapy is associated with metabolic improvement and insulin dose reduction in commonly prescribed insulin regimens

Piya Sen Gupta¹, Ken Y Thong², Christopher Walton³, Robert EJ Ryder¹, on behalf of ABCD liraglutide audit contributors

¹City Hospital, Birmingham, UK

²Rockingham General Hospital, Perth, Australia

³Hull Royal Infirmary, Hull, UK

NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes: the ABCD nationwide audits

KY Thong¹, P Sen Gupta², ML Cull², KA Adamson³, DS Dove⁴, SV Rowles⁵, S Tarpey⁵, C Duncan⁶ , J Chalmers⁶, R Harper⁷, P McDonald⁷, U Brennan⁷, C Walton⁸, REJ Ryder² on behalf of the ABCD Nationwide exenatide^* and liraglutide^† audit contributors